Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.
| Revenue (Most Recent Fiscal Year) | $53.48M |
| Net Income (Most Recent Fiscal Year) | $-84.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.96 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -601.83% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -60.15% |
| Return on Assets (Trailing 12 Months) | -52.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.00 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.97 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 43.11M |
| Free Float | 38.15M |
| Market Capitalization | $111.22M |
| Average Volume (Last 20 Days) | 1.48M |
| Beta (Past 60 Months) | 0.97 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 85.09% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |